AbCellera Biologics (ABCL) Equity Average (2020 - 2025)
AbCellera Biologics (ABCL) has disclosed Equity Average for 6 consecutive years, with $985.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 9.96% year-over-year to $985.6 million, compared with a TTM value of $985.6 million through Sep 2025, down 9.96%, and an annual FY2024 reading of $1.1 billion, down 7.43% over the prior year.
- Equity Average was $985.6 million for Q3 2025 at AbCellera Biologics, down from $1.0 billion in the prior quarter.
- Across five years, Equity Average topped out at $1.2 billion in Q4 2022 and bottomed at $893.8 million in Q1 2021.
- Average Equity Average over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2022.
- The sharpest move saw Equity Average soared 1002.53% in 2021, then fell 9.96% in 2025.
- Year by year, Equity Average stood at $989.6 million in 2021, then grew by 25.48% to $1.2 billion in 2022, then decreased by 5.97% to $1.2 billion in 2023, then dropped by 8.6% to $1.1 billion in 2024, then dropped by 7.64% to $985.6 million in 2025.
- Business Quant data shows Equity Average for ABCL at $985.6 million in Q3 2025, $1.0 billion in Q2 2025, and $1.0 billion in Q1 2025.